Phase II study of ifosfamide plus vinorelbine in metastatic breast cancer patients previously treated with combination chemotherapy

Forty-six patients were included in a phase II study to evaluate the respon se rate and toxicity of a combination of ifosfamide and vinorelbine in meta static breast cancer patients previously treated with one or more regimens of chemotherapy. Treatment consisted of ifosfamide 1.6 g/m(2) IV days 1-3 ( with mesna) and vinorelbine 25 mg/m(2) IV days 1 and 8, every 3 weeks up to 6 cycles. The median age was 55 years (range 40-76), the World Health Orga nization (WHO) performance status was 0-1 in 93% of the patients and 2 in t he remaining 7%. In all, 43% had received two or more previous lines of che motherapy, and 91% had been treated with anthracyclines. Forty-four patient s were evaluable for response, and all patients for toxicity. The overall r esponse rate was 36.4% [95% confidence interval (CI) 22.4-52.2]. Stabilizat ion was observed in 20.4% and progression in 43.2%. The median time to prog ression was 25 weeks (95% CI 14-36). Median relative dose intensity (= actu al received dose intensity/planned dose intensity) was 0.99 for ifosfamide and 0.80 for vinorelbine. The main toxicity was hematological, with 63% of the patients experiencing grade 3-4 neutropenia. With a moderate toxicity, this is an active regimen that may be taken into consideration in pretreate d metastatic breast cancer patients when further chemotherapy is indicated.